Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Go back to Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases| (NASDAQ: MIRM) | Delayed: 123.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.77 | 52 Week High | $ | |||
| Open | $0.00 | 52 Week Low | $ | |||
| Day High | $123.77 | P/E | N/A | |||
| Day Low | $123.77 | EPS | $ | |||
| Volume | 0 | |||||
